Ascendis Pharma Growth Disorders A/S — Credit Rating and Financial Key Figures
CVR number: 32323677
Tuborg Boulevard 12, 2900 Hellerup
Income statement (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -30 184.95 | -47 933.48 | -57 035.67 | - 114 185.00 | - 157 522.00 |
| Costs of management | - 116.20 | - 116.47 | - 116.46 | -30.00 | -69.00 |
| EBIT | -30 301.15 | -48 049.95 | -57 152.13 | - 114 215.00 | - 157 591.00 |
| Other financial income | 0.31 | 78.00 | 69.00 | ||
| Other financial expenses | -1 858.50 | -3 026.02 | -4 305.04 | -6 259.00 | -19 069.00 |
| Pre-tax profit | -32 159.65 | -51 075.97 | -61 456.86 | - 120 396.00 | - 176 591.00 |
| Income taxes | 61.08 | 118.09 | 75.69 | 173.00 | 572.00 |
| Net earnings | -32 098.57 | -50 957.88 | -61 381.17 | - 120 223.00 | - 176 019.00 |
Assets (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible rights | 54.55 | ||||
| Intangible assets total | 54.55 | ||||
| Tangible assets total | |||||
| Participating interests | 6 529.10 | 8 439.09 | |||
| Other non-current investments | 8 439.00 | 8 439.00 | |||
| Investments total | 6 529.10 | 8 439.09 | 8 439.00 | 8 439.00 | |
| Non-current loans receivable | 8 439.09 | ||||
| Long term receivables total | 8 439.09 | ||||
| Inventories total | |||||
| Current trade debtors | 53.01 | 39.61 | 180.00 | 435.00 | |
| Prepayments and accrued income | 205.44 | 31.00 | |||
| Current other receivables | 2 036.20 | 1 043.40 | 5 129.23 | ||
| Short term receivables total | 2 241.64 | 1 096.40 | 5 168.84 | 211.00 | 435.00 |
| Cash and bank deposits | 1 905.39 | 10.51 | 7.45 | 12 972.00 | 59.00 |
| Cash and cash equivalents | 1 905.39 | 10.51 | 7.45 | 12 972.00 | 59.00 |
| Balance sheet total (assets) | 10 730.68 | 9 546.00 | 13 615.38 | 21 622.00 | 8 933.00 |
Equity and liabilities (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 67.02 | 67.02 | 67.02 | 67.00 | 67.00 |
| Share premium account | -50.27 | -50.00 | |||
| Other reserves | -50.27 | -50.27 | |||
| Retained earnings | -57 402.09 | -89 500.66 | - 140 458.54 | - 201 840.00 | - 322 063.00 |
| Profit of the financial year | -32 098.57 | -50 957.88 | -61 381.17 | - 120 223.00 | - 176 019.00 |
| Shareholders equity total | -89 483.90 | - 140 441.79 | - 201 822.96 | - 322 046.00 | - 498 015.00 |
| Non-current owed to group member | 97 208.89 | 149 981.91 | 215 432.42 | 343 661.00 | 506 938.00 |
| Non-current liabilities total | 97 208.89 | 149 981.91 | 215 432.42 | 343 661.00 | 506 938.00 |
| Other non-interest bearing current liabilities | 3 005.69 | 5.88 | 5.92 | 7.00 | 10.00 |
| Current liabilities total | 3 005.69 | 5.88 | 5.92 | 7.00 | 10.00 |
| Balance sheet total (liabilities) | 10 730.68 | 9 546.00 | 13 615.38 | 21 622.00 | 8 933.00 |
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.